Staff number : 1-9
Description of activities
AxoGlia Therapeutics SA is a biopharmaceutical company which drives the development of innovative therapeutic approach with stem/progenitor cell differentiation capacities for indications in neurology and cancer.
AxoGlia was set up to develop and commercialize the expertise gained in neurotrophic factors biomimetic and regenerative medicine for treating neurodegenerative diseases such as Multiple Sclerosis and Parkinson’s disease.
AxoGlia has built-up a portfolio of neurogenic and anti-inflammatory molecules targeting brain repair. These therapeutic candidates are optimized to improve functional integration and survival of new mature neurons.
AxoGlia has developed strong research collaboration with Professor Rudi Balling of the Luxembourg Centre for Systems Biomedicine to identify novel therapeutic targets for Parkinson’s disease.
Products and services
Research, Development and Innovation (RDI)
Patent applications filed per year: 1 : Use of external technology under a licensing agreement or acquisition: Yes
AxoGlia Therapeutics SA has concentrated its efforts on its fields of expertise: the development and the biological screening of synthetic molecules for the treatment of neuropathologies. On account of their neuroregenerative and anti-inflammatory properties, these molecules have a curative vocation, which represents a spectacular evolution for the treatment of these diseases. AxoGlia Therapeutics SA has the know-how for the development of families of innovating chemical molecules and is developing screening platforms to identify drugs that modulate the differentiation of nervous cells and having neuroprotective properties. These molecules not only have a broad utility for CNS disorders but may also have a high potential for cardiovascular, cancer, immune and inflammatory diseases.
- Life Sciences, health and biotechnology
Mr. COOWAR Djalil
Chief Scientific Officer
Phone: +352 46 66 44 64 45